Colorectal cancer (CRC) represents one of the most common cancers worldwide and 5-Fluorouracil (5-FU) is still the mainstay of treatment. However, 5-FU is often implicated in inducing oral mucositis (OM), a painful inflammatory condition that may hinder oral intake, negatively impact quality of life and disrupt adherence with cancer treatment.
Oxidative stress and inflammation play a vital role in OM pathogenesis. Alpha-lipoic acid (ALA) is a powerful antioxidant and anti-inflammatory agent that has demonstrated protective effects towards chemotherapy-induced mucosal damage in preclinical studies.
Therefore, ALA may be a promising strategy to minimize or avoid 5-FU-induced oral mucositis in patients with colorectal cancer, which deserves additional clinical investigation.
Inclusion Criteria:
Exclusion Criteria:
ghada.ms2425015@pharma.asu.edu.eg+20 01097001838
Each patient in the Control group will receive a placebo tablet which is identical in appearance, size, and color to the active treatment tablet, administered for the same duration.
ALA Group: patients will receive Alpha lipoic acid 600mg oral tablet twice daily for 6 months
Control group will receive identical placebo oral tablet twice daily for 6 months
The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma
Alpha Lipoic Acid in Ulcerative Colitis
Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis
Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients
Alpha-Lipoic Acid in Breast Cancer Patients